Abstract: A method for providing a user customized card in a launcher. A card list is presented in the launcher (1210). One or more customizable cards are provided in response to a user input (1220). A user selection of one of the one or more cards is received (1230). Customization of the selected card is executed based on user inputs (1240). The customized card is presented in the card list (1250).

Abstract: Provided are new crystalline forms A, B, C, D and E of sacubitril sodium salt and a method for preparation thereof, pharmaceutical compositions thereof, and application thereof in preparing drugs for enkephalinase-related diseases.

Abstract: The present invention relates to a cosmetic container which provides a non-woven substrate and an applicator, which may be used for the application of cosmetic or personal care compositions to the skin or hair. The non-woven substrate preferably uses crimped microfibers and may be layered, modified to include a peripheral liquid-impermeable rim, and combinations thereof. The composition of the fibers may also be tailored for maximum stability when used in combination with particular formulations, such as sunscreens.

Abstract: A method for page navigation is disclosed. A first page is presented on a display screen, a first input indicating a page moving in a first direction is received on the first page, presentation of the first page is switched to presentation of a second page, a second input indicating a page moving in a second direction is received on the second page, wherein the second direction is not collinear to the first direction, and presentation of the second page is switched to presentation of a third page.

Abstract: The disclosure relates to a method for interaction. At least one card is presented in a UI of a launcher, each of the at least one card comprises content related items associated with a category of the card. A page is presented in response to a user input indicating switching from presentation of a card to presentation of the page, the page comprises content related items associated with a category of the page, the card is of the same category as the page and comprises a subset of the content related items of the page.

Abstract: The present invention relates to a crystalline form N of aripiprazole, pharmaceutical compositions thereof and the use of crystalline form N in the preparation of a medicament for the treatment of central nervous system diseases, especially schizophrenia.

Abstract: Provided are new crystalline forms A, B, C, D and E of sacubitril sodium salt and a method for preparation thereof, pharmaceutical compositions thereof, and application thereof in preparing drugs for enkephalinase-related diseases.

Abstract: Provided are crystal forms A, B, D, E, F, G and H of valsartan disodium salt and a preparation method therefor.

Abstract: The present invention discloses method for preparing deoxycholic acid (DCA) or an ester thereof or a pharmaceutically acceptable salt thereof. Said compounds may be applied to remove a fat deposition.

Abstract: The present invention belongs to the field of pharmaceutical formulation, and particularly relates to an aripiprazole injectable suspension formulation having prolonged shelf life, and methods of using the formulation in treating schizophrenia and related diseases. In another aspect, the present invention also relates to a method of prolonging shelf life of an aripiprazole injectable suspension formulation.

Abstract: The present invention discloses method for preparing deoxycholic acid (DCA) or an ester thereof or a pharmaceutically acceptable salt thereof. Said compounds may be applied to remove a fat deposition.

Abstract: The compounds of the present invention are represented by the following compounds having Formula (I) where the substituents R, R1-R5, k, m, n, and q are as defined herein. These compounds are used in the treatment of cancer, immunologic disorders, autoimmune disorders, neurodegenerative disorders, or inflammatory disorders, infectious disease, or for providing immunosuppression for transplanted organs or tissues.

Abstract: The compounds of the present invention are represented by the following compounds having Formula I, where the substituents R1, R4, L, M, X, Y, and s are as defined herein. The compounds of the present invention are also represented by the following compounds having Formula (Ia), Formula (Ib), or Formula (Ic), where the substituents R1-R4, RX, RY, X, Y, and s are as defined herein. These compounds are used in the treatment of cancer, immunologic disorders, autoimmune disorders, neurodegenerative disorders, or inflammatory disorders or for providing immunosuppression for transplanted organs or tissues.

Abstract: In a structure for internally cooling a turbine blade, a cooling medium passage is provided in the turbine blade. The cooling medium passage has a shape in which a plurality of cylindrical spaces, each having substantially cylindrical shape, extending in parallel with each other partially overlap each other. A cooling medium supply passage that supplies a cooling medium to the cooling medium passage is connected to a portion of the cooling medium passage that includes a peripheral wall, in a direction that forms an acute angle with respect to a longitudinal direction of the cooling medium passage.

Abstract: The compounds of the present invention are represented by the following compounds having Formula (I) where the substituents R1-R10, X, Y, k, m, n, q, and s are as defined herein. These compounds are used in the treatment of cancer, immunologic disorders, autoimmune disorders, neurodegenerative disorders, or inflammatory disorders or for providing immunosuppression for transplanted organs or tissues.

Abstract: The present invention discloses method for preparing deoxycholic acid (DCA) or an ester thereof or a pharmaceutically acceptable salt thereof. Said compounds may be applied to remove a fat deposition.

Abstract: A locker system includes a body, a driving unit, and a computer unit. The body includes a casing, a separating plate, horizontal plates, vertical plates and covering plates. The separating plate is disposed inside the casing to form an accommodating space and a storage space. The horizontal plates and the vertical plates are disposed inside the accommodating space and cooperate with the casing to form accommodating subspaces. Each covering plate is pivoted to the casing. The driving unit connects to the horizontal plates and the vertical plates. The computer unit obtains the size of an object. When the size of the object exceeds a preset size, the computer unit sends a driving signal to the driving unit, and the driving unit controls at least one horizontal plate or at least one vertical plate to move into the storage space according to the driving signal to accommodate the object.

Abstract: Slurry powder cosmetic composition comprising particulates coated with a binder composition and the evaporation residue of an aqueous based composition comprising at least one water soluble or water dispersible polymer, and a method for making the composition.

Abstract: A locker system includes a body, a driving unit, and a computer unit. The body includes a casing, a separating plate, horizontal plates, vertical plates and covering plates. The separating plate is disposed inside the casing to form an accommodating space and a storage space. The horizontal plates and the vertical plates are disposed inside the accommodating space and cooperate with the casing to form accommodating subspaces. Each covering plate is pivoted to the casing. The driving unit connects to the horizontal plates and the vertical plates. The computer unit obtains the size of an object. When the size of the object exceeds a preset size, the computer unit sends a driving signal to the driving unit, and the driving unit controls at least one horizontal plate or at least one vertical plate to move into the storage space according to the driving signal to accommodate the object.

Abstract: The compounds of the present invention are represented by the following compounds having Formula (I) where the substituents R1-R10, X, Y, k, m, n, q, and s are as defined herein. These compounds are used in the treatment of cancer, immunologic disorders, autoimmune disorders, neurodegenerative disorders, or inflammatory disorders or for providing immunosuppression for transplanted organs or tissues.